Healthcare & Life Sciences
True North Therapeutics, Inc.
United States
series-c-plus
series-c-plus
Stage
3
Investors
About
True North Therapeutics, Inc. develops humanized antibodies that inhibit the classical complement pathway to treat rare complement-mediated diseases across hematology, transplantation, and dermatology.
Explore True North Therapeutics, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.